Overview

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Europe B.V.
Treatments:
Mirabegron
Tolterodine Tartrate